CL2017002676A1 - Método de monomerizacion de moléculas recombinantes de anticuerpo - Google Patents
Método de monomerizacion de moléculas recombinantes de anticuerpoInfo
- Publication number
- CL2017002676A1 CL2017002676A1 CL2017002676A CL2017002676A CL2017002676A1 CL 2017002676 A1 CL2017002676 A1 CL 2017002676A1 CL 2017002676 A CL2017002676 A CL 2017002676A CL 2017002676 A CL2017002676 A CL 2017002676A CL 2017002676 A1 CL2017002676 A1 CL 2017002676A1
- Authority
- CL
- Chile
- Prior art keywords
- antibody molecules
- recombinant antibody
- reducing agent
- monomerization method
- monomerization
- Prior art date
Links
- 239000003638 chemical reducing agent Substances 0.000 abstract 2
- IGRWHBBHXVNZEO-UHFFFAOYSA-N guanidine;hypochlorous acid Chemical compound ClO.NC(N)=N IGRWHBBHXVNZEO-UHFFFAOYSA-N 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
- C07K1/1136—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/11—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/12—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
- C07K5/123—Tripeptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1506870.3A GB201506870D0 (en) | 2015-04-22 | 2015-04-22 | Method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017002676A1 true CL2017002676A1 (es) | 2018-03-23 |
Family
ID=53299019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017002676A CL2017002676A1 (es) | 2015-04-22 | 2017-10-20 | Método de monomerizacion de moléculas recombinantes de anticuerpo |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10828366B2 (enExample) |
| EP (1) | EP3286204B1 (enExample) |
| JP (1) | JP6898251B2 (enExample) |
| KR (1) | KR20170138552A (enExample) |
| CN (1) | CN108064230B (enExample) |
| AU (1) | AU2016251620A1 (enExample) |
| BR (1) | BR112017021812A2 (enExample) |
| CA (1) | CA2981644C (enExample) |
| CL (1) | CL2017002676A1 (enExample) |
| CO (1) | CO2017010385A2 (enExample) |
| EA (1) | EA201792329A1 (enExample) |
| ES (1) | ES2846732T3 (enExample) |
| GB (1) | GB201506870D0 (enExample) |
| IL (1) | IL254765A0 (enExample) |
| MX (1) | MX2017013376A (enExample) |
| SG (1) | SG11201708151TA (enExample) |
| WO (1) | WO2016170138A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201223276D0 (en) * | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
| US10626143B2 (en) | 2014-12-22 | 2020-04-21 | Ucb Biopharma Sprl | Method of protein manufacture |
| GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| GB201506868D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
| MX2021003976A (es) * | 2018-10-11 | 2021-05-27 | Amgen Inc | Procesamiento posterior de constructos de anticuerpos biespecificos. |
| KR20210107731A (ko) * | 2018-12-21 | 2021-09-01 | 노파르티스 아게 | Pmel17에 대한 항체 및 이의 접합체 |
| IL303295A (en) * | 2020-12-07 | 2023-07-01 | UCB Biopharma SRL | Multi-specific antibodies and antibody combinations |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
| US5453363A (en) | 1985-10-23 | 1995-09-26 | Boehringer Mannheim Gmbh | Process for the activation of t-PA or Ing after genetic expression in prokaryotes |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| EP1997891A1 (en) | 1988-09-02 | 2008-12-03 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| ATE419355T1 (de) * | 1992-02-06 | 2009-01-15 | Novartis Vaccines & Diagnostic | Marker für krebs und biosynthetisches bindeprotein dafür |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
| DK1231268T3 (da) | 1994-01-31 | 2005-11-21 | Univ Boston | Polyklonale antistofbiblioteker |
| FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| ES2366100T3 (es) * | 1999-02-22 | 2011-10-17 | Georgetown University | Inmunoliposomas dirigidos mediante un fragmento de anticuerpo para la administración sistémica de genes. |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| TWI438010B (zh) | 2002-05-02 | 2014-05-21 | Wyeth Corp | 卡奇黴素（ｃａｌｉｃｈｅａｍｉｃｉｎ）衍生物-載體共軛物 |
| AU2003223936A1 (en) * | 2002-05-17 | 2003-12-02 | Kobenhavns Universitet | Method for purifying denatured proteins having a desired disulfide bond configuration |
| EP1570267B1 (en) | 2002-12-03 | 2011-10-12 | UCB Pharma, S.A. | Assay for identifying antibody producing cells |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| GB0315450D0 (en) * | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| CA2527020A1 (en) | 2003-07-01 | 2005-01-13 | Celltech R & D Limited | Modified antibody fab fragments |
| MXPA06014065A (es) | 2004-06-01 | 2007-01-31 | Genentech Inc | Conjugados de droga-anticuerpo y metodos. |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| US20060051347A1 (en) | 2004-09-09 | 2006-03-09 | Winter Charles M | Process for concentration of antibodies and therapeutic products thereof |
| WO2006047340A2 (en) * | 2004-10-22 | 2006-05-04 | Amgen Inc. | Methods for refolding of recombinant antibodies |
| CA2614082A1 (en) | 2005-07-25 | 2007-02-01 | Trubion Pharmaceuticals, Inc. | Compositions and methods for protein deaggregation |
| US20070212703A1 (en) | 2005-09-27 | 2007-09-13 | Stemmer Willem P | Proteinaceous pharmaceuticals and uses thereof |
| GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
| ES2667729T3 (es) | 2007-09-26 | 2018-05-14 | Ucb Biopharma Sprl | Fusiones de anticuerpos con doble especificidad |
| JP5529869B2 (ja) | 2008-08-14 | 2014-06-25 | メルク・シャープ・アンド・ドーム・コーポレーション | プロテインａアフィニティークロマトグラフィーを用いる抗体の精製方法 |
| WO2010035012A1 (en) | 2008-09-26 | 2010-04-01 | Ucb Pharma S.A. | Biological products |
| JP2012503487A (ja) * | 2008-09-26 | 2012-02-09 | シェーリング コーポレイション | 高力価抗体の製造 |
| EP3660032B1 (en) | 2009-06-25 | 2025-10-22 | Amgen Inc. | Capture purification processes for proteins expressed in a non-mammalian system |
| EP2475682B1 (en) | 2009-09-10 | 2018-01-31 | UCB Biopharma SPRL | Multivalent antibodies |
| GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
| CN102892780B (zh) * | 2010-03-17 | 2015-07-29 | 通益制药有限公司 | 获得生物活性的重组人g-csf的方法 |
| EP2550297B1 (en) | 2010-03-25 | 2019-01-23 | UCB Biopharma SPRL | Disulfide stabilized dvd-lg molecules |
| GB201005064D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
| CA2812058C (en) * | 2010-09-20 | 2019-04-16 | Bio-Rad Laboratories, Inc. | Dissociation of product-complexed contaminants in chromatography |
| US8759617B2 (en) * | 2010-09-21 | 2014-06-24 | National Institute Of Agrobiological Sciences | Method for extraction and purification of recombinant proteins from transgenic plants |
| AU2012305714A1 (en) * | 2011-09-09 | 2014-03-27 | Biomed Realty, L.P. | Methods and compositions for controlling assembly of viral proteins |
| SG11201401649VA (en) * | 2011-11-11 | 2014-07-30 | Ucb Pharma Sa | Albumin binding antibodies and binding fragments thereof |
| UA112203C2 (uk) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини |
| US20160060291A1 (en) * | 2012-03-30 | 2016-03-03 | Biogenomics Limited | Process for renaturation of polypeptides |
| GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
| PL2922872T3 (pl) | 2012-11-21 | 2019-03-29 | Janssen Biotech, Inc. | Bispecyficzne przeciwciała przeciwko egfr/c-met |
| CN106133137A (zh) | 2014-03-07 | 2016-11-16 | 生物纳米基因公司 | 多核苷酸的处理 |
| GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
| GB201506869D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| GB201506868D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
| GB201506870D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
| EP3485280A1 (en) | 2016-08-12 | 2019-05-22 | Lonza Ltd | Proteomic analysis of host cell proteins |
-
2015
- 2015-04-22 GB GBGB1506870.3A patent/GB201506870D0/en not_active Ceased
-
2016
- 2016-04-22 SG SG11201708151TA patent/SG11201708151TA/en unknown
- 2016-04-22 WO PCT/EP2016/059051 patent/WO2016170138A1/en not_active Ceased
- 2016-04-22 CA CA2981644A patent/CA2981644C/en active Active
- 2016-04-22 EA EA201792329A patent/EA201792329A1/ru unknown
- 2016-04-22 MX MX2017013376A patent/MX2017013376A/es unknown
- 2016-04-22 JP JP2017555223A patent/JP6898251B2/ja not_active Expired - Fee Related
- 2016-04-22 EP EP16719824.1A patent/EP3286204B1/en active Active
- 2016-04-22 KR KR1020177033853A patent/KR20170138552A/ko not_active Abandoned
- 2016-04-22 AU AU2016251620A patent/AU2016251620A1/en not_active Abandoned
- 2016-04-22 ES ES16719824T patent/ES2846732T3/es active Active
- 2016-04-22 CN CN201680022972.8A patent/CN108064230B/zh active Active
- 2016-04-22 US US15/566,307 patent/US10828366B2/en active Active
- 2016-04-22 BR BR112017021812A patent/BR112017021812A2/pt not_active Application Discontinuation
-
2017
- 2017-09-28 IL IL254765A patent/IL254765A0/en unknown
- 2017-10-11 CO CONC2017/0010385A patent/CO2017010385A2/es unknown
- 2017-10-20 CL CL2017002676A patent/CL2017002676A1/es unknown
-
2020
- 2020-10-23 US US17/078,127 patent/US11786593B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108064230A (zh) | 2018-05-22 |
| JP6898251B2 (ja) | 2021-07-07 |
| JP2018515449A (ja) | 2018-06-14 |
| CA2981644C (en) | 2023-07-04 |
| GB201506870D0 (en) | 2015-06-03 |
| SG11201708151TA (en) | 2017-11-29 |
| ES2846732T3 (es) | 2021-07-29 |
| EP3286204A1 (en) | 2018-02-28 |
| WO2016170138A1 (en) | 2016-10-27 |
| US11786593B2 (en) | 2023-10-17 |
| MX2017013376A (es) | 2017-12-07 |
| EA201792329A1 (ru) | 2018-02-28 |
| US20180117153A1 (en) | 2018-05-03 |
| CO2017010385A2 (es) | 2018-03-20 |
| BR112017021812A2 (pt) | 2018-07-10 |
| US10828366B2 (en) | 2020-11-10 |
| AU2016251620A1 (en) | 2017-10-26 |
| CN108064230B (zh) | 2021-04-06 |
| EP3286204B1 (en) | 2020-11-18 |
| CA2981644A1 (en) | 2016-10-27 |
| KR20170138552A (ko) | 2017-12-15 |
| IL254765A0 (en) | 2017-12-31 |
| US20210069328A1 (en) | 2021-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017002676A1 (es) | Método de monomerizacion de moléculas recombinantes de anticuerpo | |
| ECSP20024555A (es) | Anticuerpos especificos para cd47 y pd-l1 | |
| PE20170665A1 (es) | Anticuerpos anti-tau humanizados | |
| CO2018006590A2 (es) | Métodos y composiciones para el tratamiento de un trastorno asociado a serpinc1 | |
| MX2021014954A (es) | Composiciones y metodos para la degradacion de proteinas mal plegadas. | |
| ECSP17070399A (es) | Anticuerpos contra icos | |
| AR090973A1 (es) | Anticuerpos utiles para el diagnostico del cancer | |
| MX2019012076A (es) | Composiciones que comprenden un anticuerpo anti gen-3 de activacion del linfocito (lag-3) o un anticuerpo anti-lag-3 y un anticuerpo anti muerte celular programada 1 (pd-1) o anti ligando 1 de muerte celular programada (pd-l1). | |
| MX2018010733A (es) | Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas. | |
| BR112018067368A2 (pt) | terapia de combinação com anticorpos anti-cd73 | |
| MX2016010360A (es) | Moleculas de anticuerpo para el virus del dengue y uso de las mismas. | |
| EA201691488A1 (ru) | Молекулы антител против pd-1 и их применения | |
| CR20150493A (es) | Composiciones de amri contra el componente c5 del complemento y métodos para su uso | |
| BR112017017286A2 (pt) | protease de cisteína | |
| BR112017017284A2 (pt) | protease de cisteína | |
| WO2016062722A8 (en) | Combination | |
| CL2019001668A1 (es) | Composiciones cannabinoides novedosas y métodos para tratar la epilepsia infantil. | |
| CL2018001226A1 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| PH12022550167A1 (en) | High concentration anti-c5 formulations | |
| MX381278B (es) | Composición para la estimulación ovárica controlada. | |
| CO2018005393A2 (es) | Anticuerpos anti-htra1 y métodos de uso de los mismos | |
| MX2018002164A (es) | Anticerpo anti-epha4. | |
| MX2016013849A (es) | Un factor de secrecion de proteinas con alta eficacia secretora y un vector de expresion que lo comprende. | |
| EA201891783A1 (ru) | Композиция для растворения аморфных дитиазинов и способ ее применения | |
| CL2017002677A1 (es) | Método para incrementar el porcentaje de anticuerpos monoméricos fab-dsfv de especies multiméricas |